GlassScriptPhysician profile
Edmund J Decker
NPI 1851308779
$1,026.23
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $120.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $228.00 | 2019-2020 | |
| Amgen INC. | $127.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $93.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $84.35 | 2019-2020 | |
| Acorda Therapeutics, INC | $64.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.88 | 2019 | |
| Pfizer INC. | $48.37 | 2019 | |
| Ucb, INC. | $28.94 | 2019-2020 | |
| Promius Pharma LLC | $28.47 | 2019 | |
| Abbvie INC. | $28.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.91 | 2019 | |
| Amarin Pharma, INC. | $25.92 | 2019-2020 | |
| Eisai INC. | $25.11 | 2019 | |
| Genentech USA, INC. | $14.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.42 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13.40 | 2019 | |
| Allergan, INC. | $12.99 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.74 | 2019 | |
| Aquestive Therapeutics, INC. | $12.50 | 2019 | |
| Neurocrine Biosciences, INC. | $12.30 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.19 | 2019 | |
| Shire North American Group INC | $12.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.80 | 2019 | |
| Lilly USA, LLC | $11.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.06 | 2019 | |
| Avanir Pharmaceuticals, INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmund Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.